In research led by PhD student Jess Hearn and post-doc Isolda Romero, Peter Sadler’s group has reported in PNAS an organo-osmium anticancer compound with an unusual mechanism of action that is 49x more active than the clinical drug cisplatin in 809 cancer cell lines

http://www.targetedonc.com/articles/more-powerful-than-cisplatin-preclinical-cancer-drug-study-shows